Cutaneous tumors cease CXCL9/Mig production as a result of IFN-γ-mediated immunoediting

Journal of Immunology

Volumn 190, Issue 2, 2013, Pages 832-841

  Petro, Marianne ^a   Kish, Danielle ^a   Guryanova, Olga A ^a   Ilyinskaya, Galina ^a   Kondratova, Anna ^a   Fairchild, Robert L ^a,b   Gorbachev, Anton V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CXCL9 CHEMOKINE GENE; DOWN REGULATION; FEMALE; FIBROSARCOMA; GAMMA INTERFERON INDUCIBLE PROTEIN 10 GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; IMMUNOCOMPETENCE; IMMUNOMODULATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINE CXCL9; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; INTERFERON-GAMMA; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; SKIN NEOPLASMS;

EID: 84872177909     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201906     Document Type: Article

References (39)

1. Balwit, J. M., P. Hwu, W. J. Urba, and F. M. Marincola. 2011. The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program. J. Transl. Med. 9: 18-32.
2. Shankaran, V., H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and R. D. Schreiber. 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
3. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
4. Swann, J. B., M. D. Vesely, A. Silva, J. Sharkey, S. Akira, R. D. Schreiber, and M. J. Smyth. 2008. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl. Acad. Sci. USA 105: 652-656.
5. Worschech, A. M., M. Kmieciak, K. L. Knutson, H. D. Bear, A. A. Szalay, E. Wang, F. M. Marincola, and M. H. Manjili. 2008. Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res. 68: 2436-2446.
6. Schreiber, R. D., L. J. Old, and M. J. Smyth. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
7. Zheng, P., S. Sarma, Y. Guo, and Y. Liu. 1999. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Cancer Res. 59: 3461-3467.
8. Dumitriu, I. E., D. R. Dunbar, S. E. Howie, T. Sethi, and C. D. Gregory. 2009. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 182: 2795-2807.
9. Corzo, C. A., T. Condamine, L. Lu, M. J. Cotter, J. I. Youn, P. Cheng, H. I. Cho, E. Celis, D. G. Quiceno, T. Padhya, et al. 2010. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207: 2439-2453.
10. Smyth, M. J., N. Y. Crowe, and D. I. Godfrey. 2001. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13: 459-463.
11. Crowe, N. Y., M. J. Smyth, and D. I. Godfrey. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196: 119-127.
12. Gorbachev, A. V., H. Kobayashi, D. Kudo, C. S. Tannenbaum, J. H. Finke, S. Shu, J. M. Farber, and R. L. Fairchild. 2007. CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J. Immunol. 178: 2278-2286.
13. Tannenbaum, C. S., R. Tubbs, D. Armstrong, J. H. Finke, R. M. Bukowski, and T. A. Hamilton. 1998. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 161: 927-932.
14. Guryanova, O. A., J. A. Drazba, E. I. Frolova, and P. M. Chumakov. 2011. Actin cytoskeleton remodeling by the alternatively spliced isoform of PDLIM4/RIL protein. J. Biol. Chem. 286: 26849-26859.
15. Dufour, J. H., M. Dziejman, M. T. Liu, J. H. Leung, T. E. Lane, and A. D. Luster. 2002. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168: 3195-3204.
16. Whiting, D., G. Hsieh, J. J. Yun, A. Banerji, W. Yao, M. C. Fishbein, J. Belperio, R. M. Strieter, B. Bonavida, and A. Ardehali. 2004. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J. Immunol. 172: 7417-7424.
17. Sgadari, C., A. L. Angiolillo, B. W. Cherney, S. E. Pike, J. M. Farber, L. G. Koniaris, P. Vanguri, P. R. Burd, N. Sheikh, G. Gupta, et al. 1996. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc. Natl. Acad. Sci. USA 93: 13791-13796.
18. Sgadari, C., J. M. Farber, A. L. Angiolillo, F. Liao, J. Teruya-Feldstein, P. R. Burd, L. Yao, G. Gupta, C. Kanegane, and G. Tosato. 1997. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 89: 2635-2643.
19. Narvaiza, I., G. Mazzolini, M. Barajas, M. Duarte, M. Zaratiegui, C. Qian, I. Melero, and J. Prieto. 2000. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J. Immunol. 164: 3112-3122.
20. Dorsey, R., N. Kundu, Q. Yang, C. S. Tannenbaum, H. Sun, T. A. Hamilton, and A. M. Fulton. 2002. Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Cancer Res. 62: 2606-2610.
21. Ruehlmann, J. M., R. Xiang, A. G. Niethammer, Y. Ba, U. Pertl, C. S. Dolman, S. D. Gillies, and R. A. Reisfeld. 2001. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res. 61: 8498-8503.
22. Pertl, U., A. D. Luster, N. M. Varki, D. Homann, G. Gaedicke, R. A. Reisfeld, and H. N. Lode. 2001. IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J. Immunol. 166: 6944-6951.
23. Walser, T. C., X. Ma, N. Kundu, R. Dorsey, O. Goloubeva, and A. M. Fulton. 2007. Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model. J. Immunother. 30: 490-498.
24. Yuan, A., P. C. Yang, C. J. Yu, Y. C. Lee, Y. T. Yao, C. L. Chen, L. N. Lee, S. H. Kuo, and K. T. Luh. 1995. Tumor angiogenesis correlates with histologic type and metastasis in non-small-cell lung cancer. Am. J. Respir. Crit. Care Med. 152: 2157-2162.
25. Kondo, T., F. Ito, H. Nakazawa, S. Horita, Y. Osaka, and H. Toma. 2004. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J. Urol. 171: 2171-2175.
26. Kunz, M., A. Toksoy, M. Goebeler, E. Engelhardt, E. Bröcker, and R. Gillitzer. 1999. Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J. Pathol. 189: 552-558.
27. Dengel, L. T., A. G. Norrod, B. L. Gregory, E. Clancy-Thompson, M. D. Burdick, R. M. Strieter, C. L. Slingluff, Jr., and D. W. Mullins. 2010. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J. Immunother. 33: 965-974.
28. Harlin, H., Y. Meng, A. C. Peterson, Y. Zha, M. Tretiakova, C. Slingluff, M. McKee, and T. F. Gajewski. 2009. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69: 3077-3085.
29. O'Sullivan, T., G. P. Dunn, D. Y. Lacoursiere, R. D. Schreiber, and J. D. Bui. 2011. Cancer immunoediting of the NK group 2D ligand H60a. J. Immunol. 187: 3538-3545.
30. Gray-Schopfer, V., C. Wellbrock, and R. Marais. 2007. Melanoma biology and new targeted therapy. Nature 445: 851-857.
31. Wong, L. H., K. G. Krauer, I. Hatzinisiriou, M. J. Estcourt, P. Hersey, N. D. Tam, S. Edmondson, R. J. Devenish, and S. J. Ralph. 1997. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3g. J. Biol. Chem. 272: 28779-28785.
32. Kaplan, D. H., V. Shankaran, A. S. Dighe, E. Stockert, M. Aguet, L. J. Old, and R. D. Schreiber. 1998. Demonstration of an interferon g-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95: 7556-7561.
33. Hallermalm, K., K. Seki, A. De Geer, B. Motyka, R. C. Bleackley, M. J. Jager, C. J. Froelich, R. Kiessling, V. Levitsky, and J. Levitskaya. 2008. Modulation of the tumor cell phenotype by IFN-γ results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J. Immunol. 180: 3766-3774.
34. Mantovani, A. 1999. Chemokines. Introduction and overview. Chem. Immunol. 72: 1-6.
35. Lukacs, N. W., C. Hogaboam, E. Campbell, and S. L. Kunkel. 1999. Chemokines: function, regulation and alteration of inflammatory responses. Chem. Immunol. 72: 102-120.
36. Amichay, D., R. T. Gazzinelli, G. Karupiah, T. R. Moench, A. Sher, and J. M. Farber. 1996. Genes for chemokines MuMig and Crg-2 are induced in protozoan and viral infections in response to IFN-gamma with patterns of tissue expression that suggest nonredundant roles in vivo. J. Immunol. 157: 4511-4520.
37. Wuest, T., J. Farber, A. Luster, and D. J. Carr. 2006. CD4+ T cell migration into the cornea is reduced in CXCL9 deficient but not CXCL10 deficient mice following herpes simplex virus type 1 infection. Cell. Immunol. 243: 83-89.
38. Narumi, S., L. M. Wyner, M. H. Stoler, C. S. Tannenbaum, and T. A. Hamilton. 1992. Tissue-specific expression of murine IP-10 mRNA following systemic treatment with interferon gamma. J. Leukoc. Biol. 52: 27-33.
39. Rosenblum, J. M., N. Shimoda, A. D. Schenk, H. Zhang, D. D. Kish, K. Keslar, J. M. Farber, and R. L. Fairchild. 2010. CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors. J. Immunol. 184: 3450-3460.